Skip to main content
. Author manuscript; available in PMC: 2019 Oct 1.
Published in final edited form as: Genes Chromosomes Cancer. 2018 Aug 20;57(10):485–494. doi: 10.1002/gcc.22643

Figure 3.

Figure 3

Immunohistochemistry analysis of the selected biomarkers in AKT pathways in ULM with three different driver gene mutations/alteration. A. Photomicrographs illustrate examples of tumor sections of H/E and immunostaining (in the order of HMGA2, IGF2BP2, pAKT, and pS6,) slides for ULM with three different driver gene mutations. B. Closer view of immunoreactivity for IGF2BP2 in 6 HMGA2 (right) and 6 MED12 (left) ULM. C-E. Histobar analysis of IGF2BP (C), pAKT (D) pS6 (E) expression by immuno-intensity in ULM with different driver gene mutations and myometrium (MM).